221 related articles for article (PubMed ID: 24647611)
1. Exploring the prominent performance of CX-4945 derivatives as protein kinase CK2 inhibitors by a combined computational study.
Wang X; Pan P; Li Y; Li D; Hou T
Mol Biosyst; 2014 May; 10(5):1196-210. PubMed ID: 24647611
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
3. Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.
Liu H; Wang X; Wang J; Wang J; Li Y; Yang L; Li G
Int J Mol Sci; 2011; 12(10):7004-21. PubMed ID: 22072932
[TBL] [Abstract][Full Text] [Related]
4. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
5. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
7. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
Vahter J; Viht K; Uri A; Enkvist E
Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
[TBL] [Abstract][Full Text] [Related]
8. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
9. Structural basis of CX-4945 binding to human protein kinase CK2.
Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
[TBL] [Abstract][Full Text] [Related]
10. Structure-based identification of novel CK2 inhibitors with a linear 2-propenone scaffold as anti-cancer agents.
Qi X; Zhang N; Zhao L; Hu L; Cortopassi WA; Jacobson MP; Li X; Zhong R
Biochem Biophys Res Commun; 2019 Apr; 512(2):208-212. PubMed ID: 30878184
[TBL] [Abstract][Full Text] [Related]
11. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
Chen F; Huang X; Wu M; Gou S; Hu W
Cancer Lett; 2017 Jan; 385():168-178. PubMed ID: 27793693
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulations reveal structural insights into inhibitor binding modes and mechanism of casein kinase II inhibitors.
Ul-Haq Z; Ashraf S; Bkhaitan MM
J Biomol Struct Dyn; 2019 Mar; 37(5):1120-1135. PubMed ID: 29527958
[TBL] [Abstract][Full Text] [Related]
13. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
Dong K; Wang X; Yang X; Zhu X
J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
[TBL] [Abstract][Full Text] [Related]
14. Importance of protein flexibility on molecular recognition: modeling binding mechanisms of aminopyrazine inhibitors to Nek2.
Tang X; Wang Z; Lei T; Zhou W; Chang S; Li D
Phys Chem Chem Phys; 2018 Feb; 20(8):5591-5605. PubMed ID: 29270587
[TBL] [Abstract][Full Text] [Related]
15. An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors.
Xie H; Li Y; Yu F; Xie X; Qiu K; Fu J
Int J Mol Sci; 2015 Nov; 16(11):27350-61. PubMed ID: 26580609
[TBL] [Abstract][Full Text] [Related]
16. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
17. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
18. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Kyshenia YV; Sapelkin VM; Prykhod'ko AO; Kukharenko OP; Ostrynska OV; Yarmoluk SM
Mol Cell Biochem; 2011 Oct; 356(1-2):107-15. PubMed ID: 21735097
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel CK2 leads by cross-docking based virtual screening.
Sun H; Wu X; Xu X; Jiang Z; Liu Z; You Q
Med Chem; 2014; 10(6):628-39. PubMed ID: 24286395
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]